Bicara Therapeutics Appoints Lara Meisner as Chief Legal Officer
BOSTON, Mass., December 18, 2023 – Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the appointment of Lara Meisner as chief legal officer. Ms. Meisner will oversee all aspects of Bicara’s legal function and serve as a member of the company’s leadership team.
“We are thrilled to welcome Lara during this exciting time at Bicara following the announcement of our Series C financing last week and strong clinical development progress made this year with our first-in-class EGFR/TGF-β-trap bifunctional antibody, BCA101,” said Claire Mazumdar, Ph.D., MBA, chief executive officer of Bicara Therapeutics. “Lara’s extensive legal expertise and cross-functional leadership experience in the biopharma industry will help propel Bicara into our next phase of growth.”
“Bicara is entering an important period of growth and transformation. I look forward to working with such talented and committed colleagues to help build the company for the future and advance important new precision treatments for cancer patients, including BCA101,” said Ms. Meisner.
Lara Meisner joins Bicara with more than two decades of experience in providing counsel to public and private companies across key legal and operational functions. Prior to Bicara, Ms. Meisner served as the chief legal officer, compliance officer, and corporate secretary at Viridian Therapeutics, where as part of the executive team, she led all aspects of legal and compliance. Prior to that, Ms. Meisner served in several senior legal roles at other biotechnology companies. She has also held a variety of in-house legal positions in both public and private technology companies.
Ms. Meisner received her J.D. from the Temple University Beasley School of Law and a B.A. from the University of Michigan.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The Company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara’s lead product candidate, BCA101, is a first-in-class EGFR/TGF-β-trap bifunctional antibody in clinical development for multiple tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X.
Stern Investor Relations, Inc.